EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐ PROTECT Main Study

Margareth C Ozelo iD, Matteo Luciani iD, Heidi Glosli iD, Kaan Kavakli iD, Nasrin Samji iD, Gregory C Makris iD, Claudia Tueckmantel, Monika Maas Enriquez iD, Luciana C Oliveira iD, Shveta Gupta, Mario Guillermo Arbesú iD, Mauro Davoli iD und 2 weitere

European Journal of Haematology · 2026

DOI: 10.1111/ejh.70059 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Margareth C Ozelo und 13 weiteren Autor:innen. Beteiligte Einrichtung: University of Campinas, Hemocentro UNICAMP, Campinas, São Paulo, Brazil. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII, Polyethylene Glycols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the earlier PROTECT VIII Kids study (NCT01775618), damoctocog alfa pegol was efficacious for prevention and treatment of bleeds in children aged < 12 years with severe haemophilia A.

Objective

Assess the safety of damoctocog alfa pegol, including hypersensitivity and loss of efficacy (LoE) due to an immune response to polyethylene glycol, in children aged 7 to < 12 years with severe haemophilia A.

Methods

Alfa‐PROTECT is a phase 3, multicentre, open‐label, single‐arm study (NCT05147662). Primary endpoint was the incidence of adverse events of special interest (AESI) leading to discontinuation during the first 4 exposure days.

Results

Overall, 35 children enrolled; 32 completed the 6‐month study, 21 (60%) reported ≥ 1 AE. Median (range) treatment duration was 182 (172–198) days. All AEs were mild/moderate; 3/35 children (8.6%) had study drug‐related AEs. One (2.9%) LoE event was considered an AESI, and led to temporary treatment interruption. No AEs resulted in study drug discontinuation. The probability of < 5% of patients experiencing an AESI was 92.2%. Bleed protection was maintained with damoctocog alfa pegol prophylaxis.

Conclusions

These data confirm the safety profile of damoctocog alfa pegol in children aged 7 to < 12 years with severe haemophilia A. Secondary endpoints indicate treatment was efficacious. Trial Registration The Alfa‐PROTECT trial is registered at ClinicalTrial.gov (NCT05147662)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AFactor VIIIPolyethylene GlycolsHumansChildMaleTreatment OutcomeFemaleSeverity of Illness IndexHemorrhage

Stichwörter der Autor:innen

childrenfactor VIIIhaemophilia Apolyethylene glycolsafety

Substanzen

Factor VIIIPolyethylene Glycols

Autor:innen und Institutionen

  • University of Campinas, Hemocentro UNICAMP, Campinas, São Paulo, Brazil.
  • Bambino Gesù Children's Hospital, Rome, Italy.
  • National Center for Rare Disorders and Department of Paediatric Research, Oslo University Hospital, Oslo, Norway.
  • Department of Pediatrics, Ege University Faculty of Medicine, Bornova, Turkey.
  • Department of Pediatrics, McMaster Centre for Transfusion Research, McMaster Children's Hospital/McMaster University, Hamilton, Ontario, Canada.
  • Bayer AG, London, UK.

ORCID-Profile: Margareth C Ozelo, Matteo Luciani, Heidi Glosli, Kaan Kavakli, Nasrin Samji, Gregory C Makris, Monika Maas Enriquez, Luciana C Oliveira, Mario Guillermo Arbesú, Mauro Davoli, Anthony K C Chan, Maria E Mancuso

Förderung

  • Bayer

Zitieren

APA

Ozelo, M. C., Luciani, M., Glosli, H., Kavakli, K., Samji, N., Makris, G. C., Tueckmantel, C., Maas Enriquez, M., Oliveira, L. C., Gupta, S., Arbesú, M. G., Davoli, M., Chan, A. K. C., & Mancuso, M. E. (2026). Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐ PROTECT Main Study. European Journal of Haematology. https://doi.org/10.1111/ejh.70059

Vancouver

Ozelo MC, Luciani M, Glosli H, Kavakli K, Samji N, Makris GC, et al. Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐ PROTECT Main Study. European Journal of Haematology. 2026. doi:10.1111/ejh.70059

BibTeX
@article{Ozelo2026,
  author = {Ozelo, Margareth C and Luciani, Matteo and Glosli, Heidi and Kavakli, Kaan and Samji, Nasrin and Makris, Gregory C and Tueckmantel, Claudia and Maas Enriquez, Monika and Oliveira, Luciana C and Gupta, Shveta and Arbesú, Mario Guillermo and Davoli, Mauro and Chan, Anthony K C and Mancuso, Maria E},
  title = {Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐ PROTECT Main Study},
  journal = {European Journal of Haematology},
  year = {2026},
  doi = {10.1111/ejh.70059}
}
Kostenlos starten →